Sequent Asset Management LLC Has $608,000 Position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Sequent Asset Management LLC continued to hold its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Sequent Asset Management LLC’s holdings in Alexion Pharmaceuticals were worth $608,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock worth $2,258,467,000 after buying an additional 17,960,356 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Alexion Pharmaceuticals by 3.1% in the first quarter. Vanguard Group Inc. now owns 14,467,456 shares of the biopharmaceutical company’s stock worth $1,754,034,000 after buying an additional 433,293 shares during the last quarter. State Street Corp boosted its position in shares of Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock worth $1,369,846,000 after buying an additional 718,756 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Alexion Pharmaceuticals by 15.8% in the first quarter. Jennison Associates LLC now owns 9,622,914 shares of the biopharmaceutical company’s stock worth $1,166,682,000 after buying an additional 1,309,529 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its position in shares of Alexion Pharmaceuticals by 8.0% in the first quarter. Ameriprise Financial Inc. now owns 6,149,572 shares of the biopharmaceutical company’s stock worth $745,579,000 after buying an additional 454,069 shares during the last quarter. Institutional investors and hedge funds own 90.74% of the company’s stock.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at 133.40 on Friday. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $145.41. The stock has a 50 day moving average price of $130.85 and a 200 day moving average price of $123.13. The stock has a market capitalization of $29.77 billion, a P/E ratio of 57.85 and a beta of 1.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.48. The firm had revenue of $912 million for the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. Alexion Pharmaceuticals’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period last year, the company posted $1.13 EPS. Equities analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Sequent Asset Management LLC Has $608,000 Position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/19/alexion-pharmaceuticals-inc-nasdaqalxn-position-held-by-sequent-asset-management-llc-updated-updated.html.

A number of analysts have commented on ALXN shares. Barclays PLC reissued an “overweight” rating and issued a $155.00 target price on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. UBS AG reissued a “buy” rating and issued a $142.00 target price (up previously from $140.00) on shares of Alexion Pharmaceuticals in a report on Monday, June 26th. Deutsche Bank AG reduced their target price on Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating for the company in a report on Thursday, May 25th. Morgan Stanley reissued an “overweight” rating and issued a $153.00 target price (up previously from $141.00) on shares of Alexion Pharmaceuticals in a report on Friday, July 28th. Finally, Raymond James Financial, Inc. reissued a “strong-buy” rating and issued a $176.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, May 9th. Six research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $156.13.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 700 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the transaction, the director now directly owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bros. Advisors Lp Baker bought 1,348,955 shares of the firm’s stock in a transaction on Wednesday, June 14th. The stock was acquired at an average cost of $116.32 per share, for a total transaction of $156,910,445.60. The disclosure for this purchase can be found here. Insiders purchased a total of 2,019,734 shares of company stock worth $235,606,846 over the last ninety days. 4.35% of the stock is currently owned by corporate insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

What are top analysts saying about Alexion Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alexion Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit